Literature DB >> 2938662

Antithrombin III concentration, thrombosis, and treatment with luteinising hormone releasing hormone agonist in prostatic carcinoma.

E Varenhorst, M Svensson, H Hjertberg, E Malmqvist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2938662      PMCID： PMC1339858          DOI： 10.1136/bmj.292.6525.935

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  3 in total

1.  Effect of hormonal manipulation on antithrombin III activity in patients with prostatic carcinoma.

Authors:  C P Henny; H ten Cate; N F Dabhoiwala; H R Büller; J W ten Cate
Journal:  Eur Urol       Date:  1984       Impact factor: 20.096

2.  The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue.

Authors:  J Trachtenberg
Journal:  J Urol       Date:  1983-06       Impact factor: 7.450

3.  The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate.

Authors:  E Varnehorst; L Wallentin; B Risberg
Journal:  Urol Res       Date:  1981
  3 in total
  1 in total

Review 1.  Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.